Galapagos reported a significant turnaround in 2025, moving from an operating loss to a profit of €295.1 million, largely due to a €1.069 billion deferred income release from a collaboration. The company is strategically exiting its cell therapy business, streamlining its workforce, and focusing on immunology with promising Phase 2 data for its TYK2 inhibitor GLPG3667, while also exploring partnership opportunities. This strategic repositioning aims for business development-led growth and cash flow neutrality by late 2026.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Galapagos Posts 2025 Profit and Accelerates Strategic Exit from Cell Therapy
Galapagos reported a significant turnaround in 2025, moving from an operating loss to a profit of €295.1 million, largely due to a €1.069 billion deferred income release from a collaboration. The company is strategically exiting its cell therapy business, streamlining its workforce, and focusing on immunology with promising Phase 2 data for its TYK2 inhibitor GLPG3667, while also exploring partnership opportunities. This strategic repositioning aims for business development-led growth and cash flow neutrality by late 2026.